Keywords: cv, therapeutics, second, drug, enters, phase, iii

CV Therapeutics' second drug enters Phase III

Article | 03 July 2001

Print This

CV Therapeutics has started a Phase III trial of its second pipelinedrug, the selective A1 adenosine receptor agonist CVT-510, in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in